摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基-1,3-二甲基-1H-吡唑-5-羧酸 | 756772-34-6

中文名称
4-氨基-1,3-二甲基-1H-吡唑-5-羧酸
中文别名
——
英文名称
4-Amino-1,3-dimethyl-1H-pyrazole-5-carboxylic acid
英文别名
4-amino-2,5-dimethylpyrazole-3-carboxylic acid
4-氨基-1,3-二甲基-1H-吡唑-5-羧酸化学式
CAS
756772-34-6
化学式
C6H9N3O2
mdl
——
分子量
155.15
InChiKey
KZNQLBVFRTVUIJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    355.2±42.0 °C(Predicted)
  • 密度:
    1.46±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    81.1
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • Dipeptidyl peptidase-IV inhibitors
    申请人:Hulin Bernard
    公开号:US20050234065A1
    公开(公告)日:2005-10-20
    The invention provides compounds of Formula (I) or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R 1 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.
    该发明提供了Formula (I)的化合物或其前药,或者该化合物或前药的药用可接受盐,或者该化合物、前药或盐的溶剂化合物,其中A、N、X和R1如本文所定义;以及这些药物组合物;以及使用这些药物组合物治疗疾病的方法,包括2型糖尿病、1型糖尿病、糖耐量受损、高血糖、代谢综合征(综合征X和/或胰岛素抵抗综合征)、葡萄糖尿病、代谢性酸中毒、关节炎、白内障、糖尿病神经病、糖尿病肾病、糖尿病视网膜病、糖尿病心肌病、肥胖、由肥胖恶化的疾病、高血压、高脂血症、动脉粥样硬化、骨质疏松症、脆弱、骨质流失、骨折、急性冠状动脉综合征、生长激素缺乏引起的矮小症、多囊卵巢综合征引起的不孕症、焦虑、抑郁、失眠、慢性疲劳、癫痫、进食障碍、慢性疼痛、酒精成瘾、与肠道蠕动相关的疾病、溃疡、肠易激综合征、炎症性肠病;短肠综合征;以及预防2型糖尿病疾病进展。
  • [EN] DIPEPTIDYL PEPTIDASE-IV INHIBITORS<br/>[FR] INHIBITEURS DE DIPEPTIDYL PEPTIDASE-IV
    申请人:PFIZER PROD INC
    公开号:WO2005100334A1
    公开(公告)日:2005-10-27
    The invention provides compounds of Formula (I) or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R1 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.
查看更多